Neurocrine Biosciences
NBIX
NBIX
574 hedge funds and large institutions have $12.4B invested in Neurocrine Biosciences in 2025 Q2 according to their latest regulatory filings, with 76 funds opening new positions, 220 increasing their positions, 219 reducing their positions, and 69 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
574
Holders Change
-3
Holders Change %
-0.52%
% of All Funds
7.7%
Holding in Top 10
15
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+50%
% of All Funds
0.2%
New
76
Increased
220
Reduced
219
Closed
69
Calls
$37.7M
Puts
$27M
Net Calls
+$10.7M
Net Calls Change
-$17.5M
Top Buyers
| 1 |
JPMorgan Chase & Co
New York
|
+$200M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$194M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$146M |
| 4 |
RI
RTW Investments
New York
|
+$133M |
| 5 |
Los Angeles Capital Management
Los Angeles,
California
|
+$93.1M |
Top Sellers
| 1 |
BlackRock
New York
|
-$217M |
| 2 |
O
OrbiMed
New York
|
-$62.4M |
| 3 |
State Street
Boston,
Massachusetts
|
-$49.5M |
| 4 |
Caisse de Depot et Placement du Quebec (CDPQ)
Montreal,
Quebec, Canada
|
-$44.2M |
| 5 |
VRS
Virginia Retirement Systems
Richmond,
Virginia
|
-$42M |
